Novartis has recently announced an increase in its growth and margin targets for the year, which is the third adjustment to its financial targets in 2023.

This adjustment reflects the company's strong business performance. Analysts had expected this increase, particularly in terms of margin targets, which indicates their confidence in Novartis' ongoing success.

Despite these upward revisions, consensus estimates are expected to remain stable, suggesting that market expectations are already in line with the company's positive trajectory. Investors are closely watching these developments as Novartis continues to demonstrate resilience and growth potential in the pharmaceutical sector.